SNOA · Sonoma Pharmaceuticals, Inc.

Track SNOA — free

$1.13 -0.01 (-1.30%)

Rebalance outlook locked

Market Cap

$5.46M

4.79M

Volume · Oct 22 16.86K Avg daily vol (3M) 105.11K

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

$21.92M

Trailing 12 months

Net income (TTM)

−$2.26M

Trailing 12 months

Revenue growth YoY

+59.6%

Year over year

Operating margin

-6.4%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-48.6%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+134.4%

Year over year · more shares

Price change (1Y)

-68.8%

Trailing year

Short interest

3.4%

Latest settlement · 3.1 days to cover

View all 122 metrics

Quarterly results

Revenue Net income Net loss

▲31.1% $3.58M −$610,000 '25 Q2 ▲13.6% $3.56M −$928,000 '25 Q3 ▲9.2% $3.75M −$776,000 '25 Q4* ▲18.4% $4.01M −$1.24M '26 Q1 ▲56.6% $5.60M −$534,000 '26 Q2 ▲22% $4.35M −$819,000 '26 Q3 ▲48.1% $5.56M −$581,000 '26 Q4* LATEST ▲59.6% $6.41M −$330,000 '27 Q1

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.7 · calm Equity put/call 0.52

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −35%

below

Price vs 50-day avg −9%

below

RSI (14) 41

neutral

MACD trend Negative

52-week position 5%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −8%

trailing

6-month return −4%

trailing

YTD return −68%

this year

Relative strength −10%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Flat

1 of 14 funds reported for Sep 30 · net 0 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.44% of float · ▼ -18.4% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

14 holders — mid 3-yr range

Squeeze score 38

low risk · 0–100

Fundamentals

Strong

Revenue growth +37%

Y/Y

Gross margin 38%

contracting

EPS growth +32%

Y/Y

Free cash flow $-4.1M

Balance sheet $3.4M

net cash

Quant / Vol

risk profile

Very High

Volatility 72%

annualized · 1-yr

Max drawdown −75%

past year

ATR 5.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−35% Bearish

Price vs 50-day avg

−9% Bearish

RSI (14)

41 Neutral

MACD trend

Negative Bearish

52-week position

5% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 1 of 6

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Flat

1 of 14 funds reported for Sep 30 · net 0 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

3.44% of float · ▼ -18.4% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

14 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $1 · 5% Range high $4

vs 200-day avg -35% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
SNOA Sonoma Pharmaceuticals, Inc. this stock	$5.46M	-68.4%	+36.7%	—	3.4%
TAK Takeda Pharmaceutical Co Ltd	$64.50B	+30.6%	—	—	0.1%
GALDY Galderma Group AG	$49.23B	+1.9%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$46.52B	+28.8%	+4.3%	65.4	2.6%
HLN Haleon plc	$44.06B	+2.6%	—	—	0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders

Holders

% held: 2.3%
Reported: 1 of 14
Top holder: RENAISSANCE TECHNOLOGIES…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

164.5K

Days to cover: 3.1d
Change: -37.0K sh

View

Short Volume

Short vol %

19%

As of: Oct 22, 2026

Short Total

View

Fails to Deliver

FTD shares

2.5K

Value: $3.4K
As of: Aug 21, 2026

View

Off-Exchange

Off-exchange %

31.4%

Week of: Sep 14, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$19.5M

Net income (FY): $-3.2M
EPS diluted: $-1.89

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 6, 2026
This year: 14

View

Proposed Sales

Value

$232.5K

Shares: 86.1K
Filed: Jan 3, 2025

View

Performance

	5D	20D	120D	MTD	YTD
SNOA	+0.0%	-7.6%	-4.2%	-10.2%	-68.4%
SPY	-1.0%	-0.4%	+6.0%	+0.2%	+12.0%
vs SPY	+1.0%	-7.2%	-10.2%	-10.3%	-80.4%

Key facts CIK 1367083 CUSIP 83558L303 13F (30d) 1 filings 1 filers Visit website Investor relations

SNOA · Sonoma Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Quarterly results

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance